2018
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Antonarakis ES, Small EJ, Petrylak D, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research 2018, 24: 4662-4671. PMID: 29858218, PMCID: PMC6481607, DOI: 10.1158/1078-0432.ccr-18-0638.Peer-Reviewed Original ResearchMeSH KeywordsAcid PhosphataseCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationClinical Trials as TopicGene Expression Regulation, NeoplasticGranulocyte-Macrophage Colony-Stimulating FactorHumansLysosomal-Associated Membrane Protein 1MaleNeoplasm MetastasisNeoplasms, Hormone-DependentProstatic Neoplasms, Castration-ResistantRecombinant Fusion ProteinsT-Lymphocytes, CytotoxicTissue ExtractsConceptsSipuleucel-T treatmentMetastatic castration-resistant prostate cancerProstatic acid phosphataseOverall survivalCTL activityWeek 26Immune responseWeek 6Peripheral cellular immune responsesCytotoxic T lymphocyte activityCastration-resistant prostate cancerEfficacy of sipuleucelImproved overall survivalMedian overall survivalT lymphocyte activityT cell responsesCellular immune responsesT cell proliferationClin Cancer ResHealthy volunteer samplesCD107a expressionLonger OSLymphocyte activityCytolytic responsesTertile analysis
1999
Chemotherapy for advanced hormone refractory prostate cancer
Petrylak D. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999, 54: 30-35. PMID: 10606282, DOI: 10.1016/s0090-4295(99)00452-5.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCell DeathClinical Trials as TopicHumansMaleNeoplasms, Hormone-DependentProstatic NeoplasmsSurvival RateConceptsHormone-refractory prostate cancerRefractory prostate cancerProstate-specific antigenProstate cancerBone painAdvanced hormone-refractory prostate cancerHormone-resistant prostate cancerSerum prostate-specific antigenCombination of estramustinePhase III studySoft tissue metastasesTaxane-based therapyCombination of mitoxantroneMetastatic prostate cancerDrug Administration approvalCorticosteroid therapyHormone therapyIII studyTissue metastasesRandomized trialsTreatment optionsHistorical controlsAdministration approvalClinical practiceUS FoodDocetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Seminars In Oncology 1999, 26: 55-60. PMID: 10604271.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerProstate cancerHormone-refractory prostate cancer patientsProstate-specific antigen levelRandomized phase III trialEnd pointPrimary end pointSecondary end pointsPhase III trialsSingle institution experienceSide effect profileSouthwest Oncology GroupCombination of mitoxantroneProstate cancer patientsStandard armIII trialsOncology GroupAssessment of qualityClinical outcomesEffect profileRandomized trialsTreatment armsAntigen levelsInstitution experienceCancer patients